NCT01147861 - A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2010

Primary Completion Date

September 7, 2010

Study Completion Date

September 7, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK256073

5mg in the AM and 5mg in the PM

DRUG

GSK256073

10mg in the AM

DRUG

GSK256073

50mg in the AM

DRUG

GSK256073

25mg in the AM and 25mg in the PM

OTHER

Placebo

2 placebo tablets in the AM and 2 placebo tablets in the PM

Trial Locations (4)

GSK Investigational Site, Miami

GSK Investigational Site, Miami Gardens

GSK Investigational Site, Anniston

GSK Investigational Site, San Antonio